The global excipients market should reach nearly $6.9 billion by 2020 from approximately $6.3 billion in 2015, according to a new report from BCC Research, LLC. Growth in the demand for pharmaceuticals and biopharmaceuticals should drive market growth in the excipients market as will the development of innovative drugs for chronic diseases and an increase in generic drug production. Increased research and development spending, growing competition, looming patent expiries, new technologies, and upcoming product launches are key market drivers, as well.
While there is a need for new excipients to increase options for the formulation and delivery of the newer molecules coming through the development pipelines, few new excipients have reached the market due to high development costs and stringent regulatory requirements, according to the report. Thus, developing new excipients requires expensive and time-consuming safety evaluations. As a result, some manufacturers are concentrating on co-processing existing approved excipients. Innovative co-processed excipients, or excipient composites, are being engineered to achieve the properties of key components of the tableting blend in a single, highly flowable and compressible granular material.
“With the increasing development of new chemical entities, there is a huge opportunity for the development of co-processed excipients, and development of such innovative co-processed excipients with multi-functionality is beneficial for the market,” says BCC Research Analyst Shalini S. Dewan.
In this exclusive Drug Development & Delivery report, we uncover how leading excipient manufacturers are overcoming their own R&D challenges to deliver innovative excipients that address problems associated with both large and small molecules.
Issue: June 2016, Posted Date: 6/2/2016